Thursday, May 2, 2024

Canada’s Politics and Government News Source Since 1989

Thursday, May 2, 2024 | Latest Paper

TRENDING:

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.

Opinion
BY NIGEL RAWSON, JOHN ADAMS
November 15, 2023

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023

See all stories BY NIGEL RAWSON, JOHN ADAMS

More Opinion

Momentum is building for new homeownership solutions in Canada

OpinionBY ROB RICHARDS

Budget a stride forward for mental health as a federal priority

OpinionBY DAVE GALLSON

Health care is more than treatment—it’s time to get serious about disease prevention

OpinionBY PAMELA VALENTINE

The blue dichotomy: corporatization of Canada’s oceans

OpinionBY COURTNEY LANGILLE

Central bank independence must remain a priority

OpinionBY MICHAEL BURT, PEDRO ANTUNES

Related Stories

Ongoing uncertainty about prices will deter new drug launches in Canada

OpinionBY NIGEL RAWSON AND BRETT SKINNER

Is drug price policy evidence-based or evidence-deficient?

OpinionBY BRETT SKINNER

Time for the PMPRB to go

OpinionBY NIGEL RAWSON AND BRETT SKINNER

Don’t let the next pandemic meet this pharmaceutical sector

OpinionBY CHUKWUNONSO NWABUFO

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

OpinionBY MATTHEW HERDER AND SRINIVAS MURTHY